BRD2, a member of the bromodomain extra terminal protein family, is known to regulate the expression of 1,450 genes. It is specifically localized at promoters of target genes, and early reports from the cell mapping initiative at Quantitative Biosciences Institute Coronavirus Research Group indicate that BRD2 interacts with SARS-CoV-2 envelope proteins. It is not yet known why the virus needs BRD2, but Cayman offers a set of tools to study BRD2 activity, including TR-FRET assays, human recombinant proteins, and the compound (+)-JQ1, which competitively binds to the acetyl-lysine recognition pocket of BET bromodomains inhibiting its binding interactions.

BRD2 TR-FRET Assay Kits

TR-FRET assay formats are suited to the rapid characterization of ligands for SAR studies of therapeutic compounds in a high-throughput format.

BRD2 bromodomain 1 TR-FRET Assay Kit

BRD2 bromodomain 2 TR-FRET Assay Kit

BRD2 bromodomains 1 and 2 TR-FRET Assay Kit

We can run these assays for you! Visit our Bioanalysis Services page to learn more or request a quote.

BRD2 Proteins

BRD2 bromodomain 1 (human recombinant; GST-tagged)

BRD2 bromodomain 2 (human recombinant; GST-tagged)

BRD2 bromodomains 1 and 2 (human recombinant)

Related Bromodomain Inhibitors

ABBV-075

I-BET151

I-BET726

(+)-JQ1

(+)-JQ1 (free acid)

OTX015

PFI-1

Bromodomain Inhibitor Set (specially curated from Chemical Probe data supplied by the Structural Genomics Consortium)

See all bromodomain inhibitors available from Cayman

You May Also Be Interested In

Using Existing Therapeutics Against SARS-CoV-2	Tools to Study SARS-CoV-2-Host Interactions